Allergy Therapeutics plc announced the appointment of Shaun Furlong as an Executive Director of the Company, with effect from 8 March 2024. Shaun was appointed as the Group's Chief Financial Officer (CFO) in August 2023, having previously served as Group Financial Controller since April 2022. He brings significant financial experience, having held senior finance roles within blue-chip companies across multiple sectors, including Legal & General, Hastings Direct, Volution Group and American Express.

Shaun is a Fellow of the Institute of Chartered Accountants in England and Wales and holds a PhD in polymer chemistry from the University of Sussex. Shaun Antony Furlong, aged 48, holds an interest in 1,500 ordinary shares in the Company. In the previous five years, Shaun was a director of SAF Management Services Limited.